Varian, a Siemens Healthineers company, has obtained U.S. FDA clearance for its TrueBeam and Edge radiotherapy systems equipped with the HyperSight imaging solution. This integration enhances imaging capabilities in the radiotherapy treatment room and streamlines workflows across Varian’s linear accelerators. HyperSight technology is designed to assist clinicians in customizing treatments with greater precision for individual patients.
HyperSight imaging allows clinicians to capture high-quality images during a patient’s radiation therapy sessions, enhancing precision in targeting tumors and sparing healthy tissue. Integrated into Varian’s linear accelerators, this technology enables accurate Hounsfield Unit values from cone-beam CT (CBCT) images for treatment planning. It supports offline adaptive planning, facilitating adjustments for anatomical changes during treatment without additional CT scans.
HyperSight on TrueBeam and Edge systems captures images faster with a 50% quicker gantry rotation, reducing acquisition time notably. Traditional CBCT scans, which can take up to 60 seconds, vary by anatomical site. Shorter acquisition times help reduce motion-related artifacts caused by patient movement and may lessen patient discomfort and anxiety by decreasing time on the treatment table.
The Cancer Institute at Northwell Lenox Hill in New York was one of the early adopters of HyperSight imaging on their Halcyon system. “HyperSight imaging has allowed us to improve patient comfort by decreasing the time patients spend on the treatment table while simultaneously targeting with greater confidence,” says Wesley Talcott, MD, MBA, assistant professor and radiation oncologist, department of radiation medicine at Lenox Hill Hospital. “We look forward to further streamlining care for our patients using HyperSight.”
Launched in 2022 on Varian’s Ethos and Halcyon therapy systems, HyperSight has gained traction among clinicians and researchers. With ongoing studies in eight institutions, Varian aims to better understand HyperSight’s role in advancing care. The customer-led Intelligent Imaging Consortium, formed by Varian, facilitates collaboration and innovation among HyperSight users for trials and studies.
“As a Siemens Healthineers company, we are pioneering innovative solutions to advance radiotherapy and connect the power of imaging, both inside and outside the treatment room,” says Arthur Kaindl, head of Varian. “We are excited to expand HyperSight imaging technology to our TrueBeam and Edge platforms and further collaborate with our clinical partners to provide an integrated portfolio that connects the dots along the cancer care continuum.”
